Gilead Sciences, Inc. · Foster City, CA United States ·(NASDAQ (GS): GILD)
Company Description
- #89 in FT Global 500
- #444 in FORTUNE 500
- S&P 500
Gilead Sciences has biotech balms for infectious diseases, including hepatitis, HIV, and infections related to AIDS. The company's HIV franchise includes blockbuster Truvada, a combination of two of its other drugs, Viread and Emtriva. It co-promotes another HIV treatment, called Atripla, in the US and Europe with
Key Gilead Sciences, Inc. Financials
| Company Type | Public - NASDAQ (GS): GILD Headquarters |
| Fiscal Year-End | December |
| 2008 Sales (mil.) | $5,335.8 |
| 2008 Employees | 3,441 |
Gilead Sciences, Inc. Executives
| Title | Name & Bio | Contact |
| Chairman and CEO | John Martin | Network |
| President and COO | John Milligan | Network |
| SVP and CFO | Robin Washington | Network |
